Author

KR Kalari

Observed names: K Kalari, K. Kalari, K. R. Kalari

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic in Florida, RIKEN Center for Integrative Medical Sciences, Myriad Genetics, Canadian Cancer Trials Group

OpenAlex ID: A5024901648

Abstract P3-07-29: Role of germline BRCA status and tumor homologous recombination (HR) deficiency in response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy

2016 · JC Boughey, KR Kalari, et al. · Cancer Research · 2

Abstract P3-08-01: Characteristics, outcomes and prognostic factors of luminal androgen receptor (LAR) triple-negative breast cancer (TNBC)

2019 · RA Leon-Ferre, M-Y Polley, et al. · Cancer Research · 1

Abstract P3-07-51: Regulation of DNA methyltransferases via TRAF6 determines breast cancer response to decitabine

2016 · J Yu, B Qin, et al. · Cancer Research · 1

Abstract PS1-10-22: Tumor-infiltrating lymphocytes in advanced ER-positive, HER2-negative breast cancer prior to treatment with palbociclib and endocrine therapy: a retrospective analysis of the PROMISE study

2026 · C. C. O'Sullivan, A. M. Moyer, et al. · Clinical Cancer Research

Abstract PS2-11-08: Stemness-targeted therapies to enhance the efficacy of AURKA inhibitors in endocrine resistant er+ breast cancer

2026 · A. B. D'ASSORO, M. Drago, et al. · Clinical Cancer Research

Abstract P1-03-04: Molecular subtyping of androgen receptor-positive patients using gene expression profiles

2019 · KJ Thompson, T Alaparthi, et al. · Cancer Research

Abstract P3-06-10: Multiscale modeling of omics data for precision breast cancer treatment

2019 · KR Kalari, JP Sinnwell, et al. · Cancer Research

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

2019 · CC O'Sullivan, VJ Suman, et al. · Cancer Research

Abstract P5-07-01: LncRNA MIR2052HG regulates ERα level and endocrine resistance through LMTK3 by recruiting early growth response protein 1

2018 · J Cairns, JN Ingle, et al. · Cancer Research

Abstract P3-05-06: Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and its relation to stromal tumor infiltrating lymphocytes (sTILs) in triple negative breast cancer (TNBC)

2018 · RA Leon-Ferre, M-Y Polley, et al. · Cancer Research

Abstract P5-04-01: ERβ elicits tumor suppressive effects in triple negative breast cancer through the induction of cystatins and suppression of TGFβ signaling

2016 · J Reese, E Bruinsma, et al. · Cancer Research

Abstract P4-04-05: Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes

2016 · AM Moyer, JC Boughey, et al. · Cancer Research

Abstract P1-08-10: Integration of next generation sequencing (NGS) and patient derived xenografts (PDX) to identify novel markers of paclitaxel (T) response in the breast cancer genome guided therapy study (BEAUTY)

2013 · MP Goetz, JC Boughey, et al. · Cancer Research

Works count: 13

Citation count: 4

H-index: 1

I10-index: